Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 84.2% in November

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 30,900 shares, a decline of 84.2% from the October 31st total of 195,700 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 1,720,000 shares, the short-interest ratio is presently 0.0 days.

Windtree Therapeutics Trading Up 8.2 %

Shares of WINT stock opened at $0.61 on Thursday. The firm has a fifty day simple moving average of $1.12 and a 200-day simple moving average of $3.88. The company has a market capitalization of $359,782.00, a PE ratio of -0.02 and a beta of 0.64. Windtree Therapeutics has a twelve month low of $0.45 and a twelve month high of $22.36.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.